Loading
A phase 3 trial of capecitabine in colorectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, now recruiting.
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA is a phase 3, randomised interventional study registered as NCT05797077 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 346 participants, started 2023-02-20 and due to reach its primary completion in 2029-02-20. Interventions recorded: Colorectal resection surgery.; FOLFOX chemotherapy regimen; Capecitabine. Conditions listed: Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Cancer, Therapy-Related. Primary outcome: 3-years Progression Free Survival; 5-years Progression Free Survival. Colorectal eligibility wording from the registry: "Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect);". Sites: China. No results are recorded here; the registry entry is the source.
Shares MRD / molecular residual disease testing, Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.